More pressure to justify cost of cancer drugs versus benefits

See on Scoop.itAdvocacy Action & Issues in Cancer

(Reuters) – Medical providers have begun to think more about cost, as well as safety and effectiveness, when they decide on cancer treatments.In the past, pharmaceutical companies could launch a high-priced…

Heather Swift‘s insight:

Pharma Industry Under Pressure To Justify Cancer Drugs Costs.

Reuters (12/14, Beasley) reports that incentive-based provisions in the Affordable Care Act that were devolved to improve the quality of healthcare have many hospital and other providers paying more attention to not only the safety and effectiveness, but also the costs, of potential cancer treatments. This means that pharmaceutical companies will soon be unable to tack a high price tag onto much-needed cancer therapies when they’re released on the market. Reuters cites a recent PwP poll, which found that already, about 20 percent of health insurers in the US are requiring drug companies to show that new drugs either save costs or are clinically superior to treatments already on the market before they agree to include the medications on their coverage lists.

See on www.reuters.com

Advertisements
Comments
One Response to “More pressure to justify cost of cancer drugs versus benefits”
  1. Reblogged this on The Other Side of the Stethoscope and commented:

    Pharma Industry Under Pressure To Justify Cancer Drugs Costs.

    Reuters (12/14, Beasley) reports that incentive-based provisions in the Affordable Care Act that were devolved to improve the quality of healthcare have many hospital and other providers paying more attention to not only the safety and effectiveness, but also the costs, of potential cancer treatments. This means that pharmaceutical companies will soon be unable to tack a high price tag onto much-needed cancer therapies when they’re released on the market. Reuters cites a recent PwP poll, which found that already, about 20 percent of health insurers in the US are requiring drug companies to show that new drugs either save costs or are clinically superior to treatments already on the market before they agree to include the medications on their coverage lists.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: